Therapeutic Research in Multiple Myeloma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to learn how myeloma cells grow and become a cancer, how to distinguish them from normal cells and how to eliminate these cells selectively.
| Condition | Intervention |
|---|---|
|
Multiple Myeloma |
Other: No drugs are involved |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | UARK 91-004 Therapeutic Research in Multiple Myeloma |
- A bone marrow aspirate and biopsy
- Blood
- Fine Needle aspirates
- Swabs of skin, throat, other sites
| Estimated Enrollment: | 5000 |
| Study Start Date: | August 2003 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | July 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| patients with myeloma/related diseases |
Other: No drugs are involved
No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Other Name: none, no treatment
|
Detailed Description:
Participating in this study will require that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral blood/tissue samples will be collected for research purposes, as well as testing for genetic traits of Castleman's disease if you consent to this study. In addition, data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Samples will be studied in the laboratory and in experimental animal models. These analyses and animal models may help to better understand multiple myeloma and to better select the appropriate treatment for all participants with multiple myeloma.
Inclusion Criteria:
- Any subject evaluated for a MIRT protocol
Exclusion Criteria:
- Subjects who have not been evaluated for a MIRT protocol
Contacts and Locations| Contact: Nathan Petty, MS | 5015266990 ext 2435 | pettynathanm@uams.edu |
| United States, Arkansas | |
| University of Arkansas for Medical Sciences/MIRT | Recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| Sub-Investigator: Monica Grazziutti, MD | |
| Sub-Investigator: Frits van Rhee, MD | |
| Sub-Investigator: Sarah Waheed, MD | |
| Sub-Investigator: Alejandro Restrepo, MD | |
| Sub-Investigator: Al-Ola Abdallah, MD | |
| Sub-Investigator: Jameel Muzaffar, MD | |
| Sub-Investigator: Nisar Ahmad, MD | |
| Sub-Investigator: Saad Usmani, MD | |
| Sub-Investigator: Sajjad Haider, MD | |
| Sub-Investigator: Senu Apewokin, MD | |
| Sub-Investigator: Shebli Atrash, MD | |
| Sub-Investigator: Zainab Shahid, MD | |
| Sub-Investigator: Aziz Bakhous, MD | |
| Sub-Investigator: Surachit Kumar, MD | |
| Principal Investigator: | Bart Barlogie, MD, PhD | UAMS Myeloma Institute for Research and Therapy |
More Information
No publications provided
| Responsible Party: | University of Arkansas |
| ClinicalTrials.gov Identifier: | NCT00572338 History of Changes |
| Other Study ID Numbers: | UARK 91-004 |
| Study First Received: | December 11, 2007 |
| Last Updated: | February 19, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013